Health & Biotech Creso doubles down on LatAm with Brazil cannabis import licence April 19, 2019 Special Report: Creso Pharma has won a Brazil import licence for its cannaQIX®50 medical cannabis. South America is the next… Suda Pharmaceuticals just got some bad news about its anti-malaria mouth spray April 19, 2019 Suda Pharmaceuticals (ASX: SUD) has had a setback in the development of its ArTiMist anti-malaria mouth spray. In short; it… Bacteria-killing biotech company Next Science broke onto the ASX with a 35 per cent gain April 18, 2019 Biotech company Next Science (ASX: NXS) has made an auspicious start to life as a listed company. It hit the… Health: Bubs gets national deal with Chemist Warehouse, extra China route, share spike April 18, 2019 Infant formula maker Bubs (ASX: BUB) has stitched up a deal with Chemist Warehouse, Australia's largest pharmacy retailer. The binding… MGC Pharma jumps on the China export train, shares rise 38pc April 18, 2019 Special Report: Biopharma company MGC Pharma will sell its CBD and hemp-based Nutraceuticals products in China thanks to a tie-up… Smiles takes ex-CEO, chair to court alleging illegal payments April 17, 2019 Smiles Inclusive (ASX:SIL) is taking its former CEO and chairman to court over allegations of illegal payments and transactions. The… Health: Paradigm in ‘no rush’ to partner with big pharma but analysts are alarmed April 17, 2019 The chief of knee pain biotech Paradigm Biopharmaceuticals (ASX:PAR) says his company is in no rush to take the tried-and-true exit strategy… Health: The cash keeps pouring in for Osprey, selling US$826k in devices last quarter April 16, 2019 When your sole revenue source is a medical device costing $US350 each, you'd think cash would be difficult to come… Australia and NZ will be drowning in milk by 2027 unless China laps it up April 16, 2019 International demand -- particularly from China -- will bolster the Australian dairy formula industry as modest growth forecasts are predicted… Koligo slashes IPO valuation by 33pc after institutions give it the side-eye April 15, 2019 Stem-cell-but-not company Koligo Therapeutics (ASX:KOL) has had to make some radical changes to its IPO offer. The company has dropped… Next» « Previous